Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA-23c (miR-23c) is a member of the microRNA family, a class of small non-coding RNAs (typically 19–25 nucleotides) that regulate gene expression primarily by binding to complementary sequences in the 3′ untranslated regions (3′-UTRs) of target messenger RNAs (mRNAs), resulting in translational repression or mRNA degradation[3]. miR-23c shares its seed sequence with miR-23a-3p and miR-23b-3p, forming part of the same microRNA family[1]. Recent studies have identified significant downregulation of miR-23c expression during prostate cancer progression, particularly in bone metastases compared to localized prostate cancer and benign tissue. Forced overexpression of miR-23c in prostate cancer cell lines reduces cell proliferation in vitro, suggesting tumor suppressor-like properties, though in vivo evidence for tumor suppression is limited[1]. The expression and functional effects of miR-23c in other tissues and disease contexts remain less characterized.
Not established for drugs; microRNA-23c acts through post-transcriptional repression of mRNA targets
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA-23c (miR-23c).